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Several drugs have been associated with an increased risk of heart valve disease. Numerous
reports have shown an unquestionable association between ﬁbrotic valve disease and the
following drugs: rye ergot alkaloids, such as methysergide (sold as Desernil® in France) and
ergotamine (Gynergene®), used as migraine drugs [1]; appetite suppressants, such as fen-
ﬂuramine (Ponderal®) and dexfenﬂuramine (Isomeride®) [2], also known for their link with
precapillary pulmonary hypertension (PPH) [3]; and ergotic dopaminergic agonists [1,4],
such as pergolide (Celance®) and cabergoline (Dostinex®). The so-called ‘recreational’
drug 3,4-methylene-dioxy-methylamphetamine (better known as ‘ecstasy’ [5]) has also
been potentially associated with ﬁbrotic valvular disease. Benﬂuorex was withdrawn from
sale in France in November 2009 and from the European market in June 2010 following
reports strongly suggesting an increased risk of valvular disease and PPH in patients with
previous exposure to this drug. In France, benﬂuorex was prescribed as an adjuvant to anInsufﬁsance
valvulaire ;
Benﬂuorex
appropriate diet in overweight diabetics; its indication as an adjuvant to an appropriate
diet in patients with hypertriglyceridaemia was withdrawn in 2007, following assessment
of a very poor efﬁcacy in this setting. Benﬂuorex had also been widely prescribed in France
as an appetite suppressant.
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Figure 1. Restrictive moderate mitral regurgitation in a
benﬂuorex-treated female patient. Two-dimensional echocardio-
graphic four-chamber view in systole A. The mitral leaﬂets have
lost their ﬂexibility (note marked thickening of the mitral subvalvu-
lar apparatus, with slight thickening of both leaﬂets) B. Moderate
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In France, about 2.9 million people have been exposed
or more than 3months to benﬂuorex since its market
aunch in 1976. At the time of its market withdrawal,
ver 300,000 patients were still taking the drug. French
ealthcare authorities recommend that patients who have
aken benﬂuorex should consult their primary care physi-
ian for a clinical examination, including an interview and
ardiac auscultation. If there is the slightest suspicion
f heart valve disease or if the patient requests it, the
erformance of a clinical examination and transthoracic
chocardiography by a cardiologist is further recom-
ended.
Recent literature reports [6—14] have established that
enﬂuorex can cause restrictive leaky valve damage. All four
alves can be affected but aortic and/or mitral regurgitation
redominates [10]. Aortic regurgitation seems more fre-
uent than mitral regurgitation. Dual restrictive mitroaortic
egurgitation is suggestive of drug-induced valvular disease
10]. The precise prevalence of this type of regurgitation is
ot yet known. Severe regurgitation seems to be rare, esti-
ated at less than one case per 1000 exposed patient-years
14], whereas mild valve disease appears to be more fre-
uent. Drug-induced ﬁbrotic valve disease is generally not
esponsible for severe valve stenosis.
Echocardiography is the key examination for screening
nd grading iatrogenic valve disease [15]. The echocar-
iographic features are similar for all drug-induced valve
iseases. This type of valve regurgitation can be discovered
ate on, if echocardiography has not been performed since
he withdrawal of the drug. The echocardiographic signs of
his type of damage are not often described in the litera-
ure and thus are not always well known. It is possible that
onfusion between unrecognized drug-induced valve disease
nd supposedly rheumatic valve disease has contributed to
he delay in recognizing this speciﬁc pathology in France.
oreover, it can be difﬁcult to attribute a causal relation-
hip between a speciﬁc drug and valve damage because,
n the vast majority of cases, pretreatment echocardio-
raphic data are not available. In fact, mere detection of
egurgitation does not provide information about aetiology.
estricted valve motion, which is responsible for the regur-
itation, is the most characteristic feature of drug-induced
alve disease. Hence, diagnosis-using echocardiography is
ainly based on studying the texture and motion of the
alves, and analysing the subvalvular apparatus. Typically,
ne can see generally mild or moderate valve thicken-
ng in the absence of calciﬁcation or marked commissural
usion (in contrast with rheumatic valve disease). Never-
heless, drug-induced valve disease can probably develop
n pre-existing valve lesions. Conversely, calciﬁcation might
ubsequently occur in drug-induced valve lesions.
In mitral valve regurgitation, leaﬂet thickening is often
inimal and is generally associated with thickening and
hortening of the chordae tendineae (Fig. 1). The leaﬂets
ecome retracted and less ﬂexible, which reduces valve
obility. In severe cases, leaﬂets may have a typical drum-
tick appearance with abnormal valve coaptation in systole
ausing the leak. The restriction generally affects both
itral leaﬂets but often predominates at the posterior
eaﬂet. In aortic regurgitation, valve thickening is often
ild (and may not be present). Variable degrees of leaﬂet
etraction are observed, responsible for malcoaptation and
w
f
o
uestrictive central mitral regurgitation due to restricted motion of
he two leaﬂets.
egurgitation during diastole (Fig. 2). Using two-dimensional
chocardiography, a small central triangular valve hiatus
uring diastole is observed in the short-axis view, sometimes
ssociated in the long-axis view with a subtle dome-like
spect of the aortic valve during systole. Aortic regurgitation
isualized with colour Doppler is generally central (Fig. 2).
ricuspid and pulmonary regurgitations are less common but
re similar to mitral/aortic lesions.
If valve regurgitation is present, its impact on the ventri-
le and atrium and the severity of regurgitation must always
e assessed. It is important, whenever possible, to estimate
ulmonary arterial pressure using continuous wave Doppler,
y measuring the maximum velocity of the tricuspid regurgi-
ant ﬂow. One must also look for indirect signs of PPH (septal
otion, pulmonary acceleration time, etc.).
In terms of differential diagnoses, some features of
estrictive regurgitation related to other aetiologies must
e looked for (left ventricular remodelling in ischaemic
itral insufﬁciency, rheumatic damage, inﬂammatory dis-
ase, tricuspid regurgitation in carcinoid syndromes, etc.).
he main differential diagnosis is rheumatic valve disease,
hich generally includes a certain degree of commissural
usion and often marked valve thickening [10]. Conversely, if
ne discovers unexplained restrictive mitral valve disease or
nusual central aortic regurgitation, the interview can focus
Benﬂuorex-related heart valve and echocardiography
Figure 2. Aortic valve regurgitation in a benﬂuorex-treated
female patient A. Transoesophageal two-dimensional echocardio-
graphic long-axis view in diastole: the aortic cusps are slightly
thickened, restrictive and ﬁbrous looking, with defective central
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[coaptation B. Central aortic regurgitation on colour Doppler: the
regurgitant jet diameter at the vena contracta is 6mm.
on whether the patient has taken benﬂuorex, other anorex-
ients (fenﬂuramine or dexfenﬂuramine), rye ergot alkaloids
or pergolide.
There are no data on the natural history of benﬂuorex-
induced valve disease after withdrawal of the drug. A few
studies on fenﬂuramine users have been published [16,17].
These studies are of value, given the structural similar-
ity between benﬂuorex and fenﬂuramine; moreover the
toxic effect on heart valves is due to the same metabo-
lite (norfenﬂuramine) in both cases. The progression of
fenﬂuramine-related valve disease varies greatly from one
patient to another; it stabilizes in about one case out of
two but may also worsen or improve [17]. A follow-up study
on the course of valve regurgitation in patients exposed to
benﬂuorex is required.
In March 2011, the French High Authority for Healthcare
published guidelines on how to deal with patients exposed
to benﬂuorex in relation to the initial transthoracic Doppler
echocardiography results (http://www.has-sante.fr). In
the absence of valve abnormalities after the deﬁnitive
withdrawal of benﬂuorex, systematic echocardiographic
follow-up is not recommended. In the case of grade I and
II valve regurgitation that might be related to benﬂuo-
rex or when there is doubt, systematic echocardiographic
follow-up is recommended at 1 year and then accord-
ing to the progression of the disease. For asymptomatic
[491
rade III and grade IV regurgitation, echocardiographic
ollow-up every 6 months is recommended. The echocar-
iographic follow-up of patients with severe regurgitation
hat causes functional symptoms was not speciﬁed, as
surgical indication must be discussed and appropriate
ollow-up is thus prescribed on a case-by-case basis. Tri-
uspid regurgitation maximal velocities more than 2.8m/s
hould prompt the physician to suspect PPH; in such
context, it is advisable to refer the patient to the
egional reference centre for PPH and report the case
o the national reference centre (http://www.reseau-
tap.fr/reseau-franc¸ais-htap/carte-de-france.asp).
Lastly, cardiologists in France are required to report any
utative benﬂuorex-related grade more than or equal to 1
alve regurgitation or PPH to their corresponding Regional
harmacovigilance Centre.
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